Lindblade Kim A, Arana Byron, Zea-Flores Guillermo, Rizzo Nidia, Porter Charles H, Dominguez Alfredo, Cruz-Ortiz Nancy, Unnasch Thomas R, Punkosdy George A, Richards Jane, Sauerbrey Mauricio, Castro Julio, Catú Eduard, Oliva Orlando, Richards Frank O
Division of Parasitic Diseases, National Center for Zoonotic, Vector-Borne and Enteric Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, GA 30341, USA.
Am J Trop Med Hyg. 2007 Aug;77(2):334-41.
To eliminate transmission of Onchocerca volvulus, semiannual mass treatment with ivermectin (Mectizan; donated by Merck & Co) has been underway in Guatemala since 2000. We applied the 2001 World Health Organization (WHO) elimination criteria in the Santa Rosa focus of onchocerciasis transmission in Guatemala (10,923 persons at risk). No evidence of parasite DNA was found in 2,221 Simulium ochraceum vectors (one-sided 95% confidence interval [CI], 0-0.086%), and no IgG4 antibody positives to recombinant antigen OV16 were found in a sample of 3,232 school children (95% CI, 0-0.009%). We also found no evidence of microfilariae in the anterior segment of the eye in 363 area residents (95% CI, 0-0.08%). Our interpretation of these data, together with historical information, suggest that transmission of O. volvulus is permanently interrupted in Santa Rosa and that ivermectin treatments there can be halted.
为消除盘尾丝虫的传播，自2000年以来，危地马拉一直在开展每半年一次的伊维菌素群体治疗（美迪善；由默克公司捐赠）。我们在危地马拉圣罗莎盘尾丝虫病传播重点地区（10,923名高危人群）应用了2001年世界卫生组织（WHO）的消除标准。在2,221只奥氏蚋媒介中未发现寄生虫DNA证据（单侧95%置信区间[CI]，0 - 0.086%），在3,232名学童样本中未发现针对重组抗原OV16的IgG4抗体阳性（95% CI，0 - 0.009%）。我们还在363名地区居民的眼前节中未发现微丝蚴证据（95% CI，0 - 0.08%）。我们对这些数据的解读以及历史信息表明，圣罗莎的盘尾丝虫传播已被永久阻断，那里的伊维菌素治疗可以停止。
